Research ArticleOriginal Article
Open Access

Prognostic value of neutrophil to lymphocyte ratio and platelet counts during chemotherapy in patients with advanced gastric cancer

Bo Li, Kemeng Wang, Shuai Shi, Meng Li, Min-Ting Ma, Zhi-Guo Zhou, Zhi-Cong Wang, Ya-Ning Gong, Yajie Xiao, Liyan Zhao, Qingju Meng and Yi-Bing Liu
Saudi Medical Journal November 2023, 44 (11) 1104-1112; DOI: https://doi.org/10.15537/smj.2023.44.11.20220946

References

  1. 1.↵
    1. Fan X,
    2. Qin X,
    3. Zhang Y,
    4. Li Z,
    5. Zhou T,
    6. Zhang J, et al.
    Screening for gastric cancer in China: advances, challenges and visions. Chin J Cancer Res 2021; 33: 168–180.
    OpenUrlPubMed
  2. 2.↵
    1. Olnes MJ,
    2. Martinson HA.
    Recent advances in immune therapies for gastric cancer. Cancer Gene Ther 2021; 28: 924–934.
    OpenUrl
  3. 3.↵
    1. Siddiqui AZ,
    2. Almhanna K.
    Beyond chemotherapy, PD-1, and HER-2: novel targets for gastric and esophageal cancer. Cancers (Basel) 2021; 13: 4322.
  4. 4.↵
    1. Tsuburaya A,
    2. Guan J,
    3. Yoshida K,
    4. Kobayashi M,
    5. Yoshino S,
    6. Tanabe K, et al.
    Clinical biomarkers in adjuvant chemotherapy for gastric cancer after D2 dissection by a pooled analysis of individual patient data from large randomized controlled trials. Gastric Cancer 2021; 24: 1184–1193.
    OpenUrl
  5. 5.↵
    1. Diakos CI,
    2. Charles KA,
    3. McMillan DC,
    4. Clarke SJ.
    Cancer-related inflammation and treatment effectiveness. Lancet Oncol 2014; 15: e493–e503.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Hanahan D.
    Hallmarks of cancer: new dimensions. Cancer Discov 2022; 12: 31–46.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Murata M.
    Inflammation and cancer. Environ Health Prev Med 2018; 23: 50.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Greten FR,
    2. Grivennikov SI.
    Inflammation and cancer: triggers, mechanisms, and consequences. Immunity 2019; 51: 27–41.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Elinav E,
    2. Nowarski R,
    3. Thaiss CA,
    4. Hu B,
    5. Jin C,
    6. Flavell RA.
    Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 2013; 13: 759–771.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Park SY,
    2. Nam JS.
    The force awakens: metastatic dormant cancer cells. Exp Mol Med 2020; 52: 569–581.
    OpenUrlCrossRef
  11. 11.↵
    1. Wellenstein MD,
    2. Coffelt SB,
    3. Duits DEM,
    4. van Miltenburg MH,
    5. Slagter M,
    6. de Rink I, et al.
    Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature 2019; 572: 538–542.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Schnellhardt S,
    2. Erber R,
    3. Büttner-Herold M,
    4. Rosahl MC,
    5. Ott OJ,
    6. Strnad V, et al.
    Tumour-infiltrating inflammatory cells in early breast cancer: an underrated prognostic and predictive factor? Int J Mol Sci 2020; 21: 8238.
    OpenUrl
  13. 13.↵
    1. Tesfamariam B.
    Involvement of platelets in tumor cell metastasis. Pharmacol Ther 2016; 157: 112–119.
    OpenUrl
  14. 14.↵
    1. Li YX,
    2. Chang JY,
    3. He MY,
    4. Wang HR,
    5. Luo DQ,
    6. Li FH, et al.
    Neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR) predict clinical outcome in patients with stage IIB cervical cancer. J Oncol 2021; 2021: 2939162.
    OpenUrl
  15. 15.
    1. Lusho S,
    2. Durando X,
    3. Mouret-Reynier MA,
    4. Kossai M,
    5. Lacrampe N,
    6. Molnar I, et al.
    Platelet-to-lymphocyte ratio is associated with favorable response to neoadjuvant chemotherapy in triple negative breast cancer: a study on 120 patients. Front Oncol 2021; 11: 678315.
    OpenUrl
  16. 16.
    1. Shen YJ,
    2. Qian LQ,
    3. Ding ZP,
    4. Luo QQ,
    5. Zhao H,
    6. Xia WY, et al.
    Prognostic value of inflammatory biomarkers in patients with stage I lung adenocarcinoma treated with surgical dissection. Front Oncol 2021; 11: 711206.
    OpenUrl
  17. 17.↵
    1. Wang S,
    2. Deng Y,
    3. Yu X,
    4. Zhang XW,
    5. Huo CL,
    6. Sun ZG, et al.
    Prognostic significance of preoperative systemic inflammatory biomarkers in patients with hepatocellular carcinoma after microwave ablation and establishment of a nomogram. Sci Rep 2021; 11: 13814.
    OpenUrl
  18. 18.↵
    1. Zhang Y,
    2. Lu JJ,
    3. Du YP,
    4. Feng CX,
    5. Wang LQ,
    6. Chen MB.
    Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer. Medicine (Baltimore) 2018; 97: e0144.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. He Q,
    2. Li G,
    3. Ji X,
    4. Ma L,
    5. Wang X,
    6. Li Y, et al.
    Impact of the immune cell population in peripheral blood on response and survival in patients receiving neoadjuvant chemotherapy for advanced gastric cancer. Tumour Biol 2017; 39: 1010428317697571.
    OpenUrl
  20. 20.↵
    1. Shelat VG.
    Role of inflammatory indices in management of hepatocellular carcinoma-neutrophil to lymphocyte ratio. Ann Transl Med 2020; 8: 912.
    OpenUrl
  21. 21.↵
    1. Balkwill F,
    2. Mantovani A.
    Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539–545.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Yan M,
    2. Jurasz P.
    The role of platelets in the tumor microenvironment: from solid tumors to leukemia. Biochim Biophys Acta 2016; 1863: 392–400.
    OpenUrlCrossRef
  23. 23.↵
    1. Ardi VC,
    2. Kupriyanova TA,
    3. Deryugina EI,
    4. Quigley JP.
    Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci U S A 2007; 104: 20262–20267.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Uribe-Querol E,
    2. Rosales C.
    Neutrophils in cancer: 2 sides of the same coin. J Immunol Res 2015; 2015: 983698.
    OpenUrl
  25. 25.↵
    1. Granot Z,
    2. Jablonska J.
    Distinct functions of neutrophil in cancer and its regulation. Mediators Inflamm 2015; 2015: 701067.
    OpenUrlCrossRef
  26. 26.↵
    1. Jablonska E,
    2. Puzewska W,
    3. Grabowska Z,
    4. Jablonski J,
    5. Talarek L.
    VEGF, IL-18 and NO production by neutrophils and their serum levels in patients with oral cavity cancer. Cytokine 2005; 30: 93–99.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Galon J,
    2. Costes A,
    3. Sanchez-Cabo F,
    4. Kirilovsky A,
    5. Mlecnik B,
    6. Lagorce-Pagès C, et al.
    Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960–1964.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Verma NK,
    2. Wong BHS,
    3. Poh ZS,
    4. Udayakumar A,
    5. Verma R,
    6. Goh RKJ, et al.
    Obstacles for T-lymphocytes in the tumour microenvironment: therapeutic challenges, advances and opportunities beyond immune checkpoint. EBioMedicine 2022; 83: 104216.
    OpenUrl
  29. 29.↵
    1. Gawaz M,
    2. Langer H,
    3. May AE.
    Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378–3384.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. Mezouar S,
    2. Frère C,
    3. Darbousset R,
    4. Mege D,
    5. Crescence L,
    6. Dignat-George F, et al.
    Role of platelets in cancer and cancer-associated thrombosis: experimental and clinical evidences. Thromb Res 2016; 139: 65–76.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Zurlo IV,
    2. Schino M,
    3. Strippoli A,
    4. Calegari MA,
    5. Cocomazzi A,
    6. Cassano A, et al.
    Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer. Cancer Immunol Immunother 2022; 71: 45–55.
    OpenUrl
  32. 32.
    1. Jung MR,
    2. Park YK,
    3. Jeong O,
    4. Seon JW,
    5. Ryu SY,
    6. Kim DY, et al.
    Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol 2011; 104: 504–510.
    OpenUrlCrossRefPubMed
  33. 33.
    1. Cho IR,
    2. Park JC,
    3. Park CH,
    4. Jo JH,
    5. Lee HJ,
    6. Kim S, et al.
    Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric cancer. Gastric Cancer 2014; 17: 703–710.
    OpenUrlCrossRefPubMed
  34. 34.
    1. Shin K,
    2. Jung EK,
    3. Park SJ,
    4. Jeong S,
    5. Kim IH,
    6. Lee MA.
    Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy. World J Gastrointest Oncol 2021; 13: 915–928.
    OpenUrlCrossRef
  35. 35.↵
    1. Sato S,
    2. Kunisaki C,
    3. Takahashi M,
    4. Kubo H,
    5. Tsuchiya N,
    6. Sato K, et al.
    High postoperative neutrophil-lymphocyte ratio and low preoperative lymphocyte-monocyte ratio predict poor prognosis in gastric cancer patients receiving gastrectomy with positive lavage cytology: a retrospective cohort study. Langenbecks Arch Surg 2021; 406: 2295–2303.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Fan X,
    2. Wang D,
    3. Zhang W,
    4. Liu J,
    5. Liu C,
    6. Li Q, et al.
    Inflammatory markers predict survival in patients with advanced gastric and colorectal cancers receiving anti-PD-1 therapy. Front Cell Dev Biol 2021; 9: 638312.
    OpenUrl
  37. 37.↵
    1. Fu S,
    2. Niu Y,
    3. Zhang X,
    4. Zhang JR,
    5. Liu ZP,
    6. Wang RT.
    Squamous cell carcinoma antigen, platelet distribution width, and prealbumin collectively as a marker of squamous cell cervical carcinoma. Cancer Biomark 2018; 21: 317–321.
    OpenUrl
  38. 38.↵
    1. Egan K,
    2. Crowley D,
    3. Smyth P,
    4. O’Toole S,
    5. Spillane C,
    6. Martin C, et al.
    Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells. PLoS One 2011; 6: e26125.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Burn J,
    2. Sheth H,
    3. Elliott F,
    4. Reed L,
    5. Macrae F,
    6. Mecklin JP, et al.
    Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet 2020; 395: 1855–1863.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Tatli AM,
    2. Urakci Z,
    3. Tastekin D,
    4. Koca D,
    5. Goksu SS,
    6. Uyeturk U, et al.
    A retrospective evaluation of geriatric patients with gastric cancer receiving systemic chemotherapy. J Cancer Res Ther 2020; 16: S138–S143.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords